TSLP and asthma: However, the unique action of tezepelumab-ekko on TSLP—an upstream regulator of multiple inflammatory pathways—suggests a broad potential application in severe asthma, particularly in phenotypes not adequately controlled by current biologic therapies targeting more downstream molecules.